New technology licensed by Pain Therapeutics for treating hemophilia

Do you know that Hemophilia is a rare inherited blood clotting disorder which affects more than 4, 00,000 people worldwide? In order to cure this disease, Pain Therapeutics has licensed a new technology for treatment of this disorder. It was Stanford University School of Medicine which originally developed this technology and it would be entering the clinic by 2008. Remi Barbier, President and CEO, Pain Therapeutics stated: This licensing is part of our strategy to develop novel drug candidates in hematology/oncology, while maintaining a business model that requires a modest outlay of cash. Within a year the company would be developing a novel drug candidate which would be targeting major mechanism underlying hemophilia as per Ethical Hacking. Though the basic research would be undertaken at Stanford Pain Therapeutics would be focusing on the clinical program. Let’s hope that this time we are able to eradicate this disease from this world. Via prnewswire

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>